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Abstract
Epithelial splicing regulatory protein 1 (ESRP1) binds the FGFR-2 auxiliary cis-element ISE/
ISS-3, located in the intron between exon IIIb and IIIc, and primarily promotes FGFR-2 IIIb 
expression. Here we assessed the role of ESRP1 in pancreatic ductal adenocarcinoma (PDAC). 
Immunohistochemical analysis was performed using anti-ESRP1, FGFR-2 IIIb and FGFR-2 IIIc 
antibodies in 123 PDAC cases. ESRP1-expression vector and small interference RNA (siRNA) 
targeting ESRP1 were transfected into human PDAC cells, and cell growth, migration and 
invasion were analyzed. In vivo heterotopic and orthotopic implantations using ESRP1 
overexpression clones were performed and effects on pancreatic tumor volumes and hepatic and 
pulmonary metastases determined. ESRP1 immunoreactivity was strong in the nuclei of cancer 
cells in well-to-moderately differentiated PDACs, but weak in poorly-differentiated cancers. Well-
to-moderately differentiated cancers also exhibited high FGFR-2 IIIb and low FGFR-2 IIIc 
expression, whereas this ratio was reversed in the poorly-differentiated cancers. Increased ESRP1 
expression was associated with longer survival by comparison with low-ESRP1 expression, and 
PANC-1 cells engineered to express ESRP1 exhibited increased FGFR-2 IIIb expression and 
decreased migration and invasion in vitro, whereas ESRP1 siRNA-transfected KLM-1 cells 
exhibited increased FGFR-2 IIIc expression and increased cell growth, migration and invasion. In 
vivo, ESRP1-overexpressing clones formed significantly fewer liver metastases as compared with 
control clones. ESRP1 regulates the expression pattern of FGFR-2 isoforms, attenuates cell 
growth, migration, invasion, and metastasis, and is a favorable prognostic factor in PDAC. 
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Therefore, devising mechanisms to up-regulate ESRP1 may exert a beneficial therapeutic effect in 
PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is associated with a dismal prognosis and 5-year 
survival rate of 6% (1). A high percentage of PDAC overexpress a number of growth factors 
and their receptors, including fibroblast growth factor receptor 2 (FGFR-2) (2, 3). The 
FGFR-2 gene encodes several splice variants by alternative splicing (4–6). FGFR-2 IIIb and 
FGFR-2 IIIc are representative FGFR-2 isoforms among several splice variants derived from 
FGFR-2. FGFR-2 IIIb and FGFR-2 IIIc are expressed predominantly in epithelial cells and 
mesenchymal cells, respectively, yet are almost identical transmembrane-type receptors with 
extracellular immunoglobulin-like domains and cytoplasmic tyrosine-kinase domain (7). 
However, FGFR-2 IIIb and FGFR-2 IIIc differ from each other in the carboxyl-terminal half 
of the third Ig-like region of the extracellular domain, as a consequence of alternative 
mRNA splicing. During epithelial to mesenchymal transition (EMT) in bladder and prostate 
cancers, there is a switching in the expression of FGFR-2 IIIb to FGFR-2 IIIc (8, 9). Both 
isoforms are expressed in PDAC, and there is a significant correlation between co-
expression of FGFR-2 IIIb and FGF7, venous invasion, vascular endothelial growth factor 
(VEGF)-A expression, and poor prognosis (2). Moreover, PDAC cell growth is suppressed 
by targeting FGFR-2 IIIc with a small interfering RNA (siRNA) or with an anti-FGFR-2 IIIc 
antibody (10).
A number of auxiliary cis-elements and RNA binding proteins that regulate splicing of 
FGFR-2 IIIb and FGFR-2 IIIc have been reported (11, 12). Epithelial splicing regulatory 
protein 1 (ESRP1) is a RNA binding protein which participates in the enhancement of 
splicing of the upstream exon IIIb while silencing the downstream exon IIIc binding intronic 
splicing enhancer/intronic splicing silencer-3 (ISE/ISS-3) (13). Furthermore, ESRP1 
orchestrates an epithelial type of splicing regulatory program in EMT (14) by regulating of 
splicing of FGFR-2, CD44, ENAH, and p120-catenin in breast, lung, colon, cancer (15, 16). 
Induction of EMT in normal human prostate epithelial cells by inducing knockdown of E-
cadherin is also associated with the downregulation of both ESRP1 and ESRP2 (13, 17). 
Moreover, ectopic forced expression of the ESRP1 in mesenchymal cells is associated with 
changes in cell morphology and motility reminiscent of an epithelial phenotype, suggesting 
that splicing regulation drives critical aspects of EMT-associated phenotypic changes (18). 
In the present study we sought to delineate the role of ESRP1 in PDAC and to assess the 
mechanisms whereby ESRP1 modulates EMT and the alternative splicing of FGFR-2.
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Results
Immunohistochemical analysis of ESRP1, FGFR-2 IIIb and FGFR-2 IIIc in human PDAC
PDAC is often associated with regions that are moderately differentiated adenocarcinoma 
which form ductal-like structures, and with regions that are poorly-differentiated and form 
alveolar or trabecular structures (Fig. 1A). ESRP1 was abundant in the nuclei of cancer cells 
that were well-to-moderately differentiated adenocarcinoma (Fig. 1A, black arrows), but 
was weakly expressed in poorly-differentiated adenocarcinoma (Fig. 1A). In serial tissue 
sections, strong expression of FGFR-2 IIIb was detected in the cytoplasm and/or cell 
membrane of well-to-moderately differentiated adenocarcinoma cells (Fig. 1A, white 
arrows), whereas weak expression was seen in poorly-differentiated adenocarcinoma. By 
contrast, FGFR-2 IIIc immunoreactivity was weak in well-to-moderately differentiated 
adenocarcinoma (Fig. 1A), and was strong in poorly-differentiated adenocarcinoma (Fig. 
1A, arrowheads). Accordingly, cancer lesions were classified into two groups: well-to-
moderately differentiated adenocarcinoma (well/mod) and poorly-differentiated 
adenocarcinoma (poor), and evaluated for ESRP1, FGFR-2 IIIb, and FGFR-2 IIIc 
immunoreactivity.
ESRP1 and FGFR-2 IIIb indices were significantly higher in well/mod lesions than those in 
poorly-differentiated lesions (P<0.01, Fig. 1B and C). By contrast, FGFR-2 IIIc indices in 
poorly-differentiated lesions were significantly higher than in well/mod lesions (P<0.05, 
Fig. 1D). In the normal human pancreas, ESRP1 immunoreactivity was detected in the 
nuclei and cytoplasm of acinar cells and in the nuclei of islet cells, but was either weak or 
undetectable in pancreatic ductal cells and absent in vascular endothelial cells (Supplemental 
Fig. 1).
Correlation of clinicopathological features with ESRP1 expression
To examine the correlation between ESRP1 expression and clinicopathological features, we 
divided 123 PDAC cases into two groups based on ESRP1 expression as determined by the 
median value for the immunohistochemical indices. The ESRP1-high group (n=65) had 
more cases with histological grade of G1/G2, whereas the ESRP1-low group (n=58) had 
more cases with G3 histology (P=0.04, Supplemental Table 1). By contrast, other 
clinicopathological factors such as age, sex, T, N, and M factors, and stage based on UICC 
classification were similar in both groups. However, the overall survival rate of the ESRP1-
high group was significantly longer than that of the ESRP1-low group (P=0.0189, Fig. 2A). 
The disease-free survival rate of the ESRP1-high group also tended to be longer than the 
ESRP1-low group (P=0.0767, Fig. 2B). Sixty-six patients received adjuvant chemotherapy 
(Supplemental table 1) with various combinations of gemcitabine, 5-fluorouracil (5-FU), 
tegafur-uracil (UFT), and TS-1 (consisting of tegafur, gimeracil and oteracil potassium). 
Excluding these patients and focusing on the surgery only group, survival was not 
statistically better in the ESRP1-high group (Supplemental Fig. 2).
Effects of transient transfection of an ESRP1-expressing vector in PANC-1 cells
To assess the role of ESPR-1 in PDAC cells we initially characterized ESRP1 expression 
and determined that it was elevated in Capan-1, KLM-1, PK-1 and PK-8 cells, and low in 
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PANC-1, PK-45H and MIA PaCa-2 cells (Supplemental Fig. 3A). FGFR-2 IIIb mRNA 
levels were also elevated in Capan-1, KLM-1, PK-1 and PK-8 cells, and low in the other 
cells (Supplemental Fig. 3B). By contrast, FGFR-2 IIIc mRNA levels were more variable, 
and were highest in PANC-1 cells (Supplemental Fig. 3C).
To examine the effects of increased ESRP1 expression we transiently transfected an ESRP1-
expression-vector into PANC-1 cells, since these cells expressed the lowest levels of 
endogenous ESRP1. Transfected cells (PANC-ESRP1) expressed high ESRP1 mRNA levels 
(P<0.01) by comparison with empty vector-transfected control cells (PANC-EV) or parental 
cells (Fig. 3A). There was a concomitant increase in FGFR-2 IIIb mRNA levels in PANC-
ESRP1 cells by comparison with PANC-EV and parental PANC-1 cells (P< 0.05), whereas 
FGFR-2 IIIc levels were not altered (Fig. 3A). Moreover, ESRP1 protein levels were 
increased in the nuclear fraction of PANC-ESRP1 cells (Fig. 3B). Phase-contrast 
microscopy did not reveal any characteristic morphological changes these cells (Fig. 3C 
upper panels). Nonetheless, by immunofluorescence, ESRP1 was increased in the nuclei of 
PANC-ESRP1 cells as compared with parental and PANC-EV cells (Fig. 3C, lower panels).
Effects of ESRP1-transfection on cell proliferation, migration and invasion in PANC-1 cells
Similar growth rates were observed in PANC-1, PANC-EV and PANC-ESRP1 cells, as 
determined in a WST-8 cell counting assay (Fig. 4A). By contrast, single cell migration of 
PANC-ESRP1 cells was significantly decreased by comparison with parental PANC-1 and 
PANC-EV cells (P<0.01, Fig. 4B), and cell migration and invasion in a modified Boyden 
chamber assay were markedly decreased as compared with PANC-EV cells (P<0.01, Fig. 
4C and D).
To confirm the results observed following transient transfection, we established PANC-1 
clones (-2 and -5) stably-expressing ESRP1, and PANC-EV2 and PANC-EV9 clones 
expressing the empty vector (Supplemental Fig. 4A). Although FGFR-2 IIIb and IIIc levels 
were variable in each clone, the mRNA ratios of FGFR-2 IIIb to FGFR-2 IIIc were higher 
by comparison with the ratios in the respective control cells, but this difference was not 
statistically significant (Supplemental Fig. 4A). Phase-contrast microscopy did not reveal 
any morphological changes in the stably transfected clones (Supplemental Fig. 4B, upper 
panels), whereas immunofluorescence revealed a marked increase in nuclear ESRP1 
(Supplemental Fig. 4B, lower panels). Importantly, ESRP1-2 and ESRP1-5 clones exhibited 
significantly attenuated single cell movement and migration as compared with PANC-EV2 
and 9 (Supplemental Fig. 5A and B).
Effects of ESRP1 silencing on KLM-1 cell proliferation, migration and invasion
We next sought to determine the consequences of ESRP1 suppression on FGFR-2 IIIb and 
IIIc levels in KLM-1 cells, since these cells expressed the highest ESRP levels among our 
cell lines. Two siRNAs targeting different sites within the ESRP1 transcript (siESRP1-A and 
siESRP1-B) were used to silence ESRP1. A siRNA (siNeg) which does not bind to any 
human mRNAs was used as a negative control. ESRP1 mRNA levels were decreased in 
siESRP1-A and siESRP1-B expressing cells, FGFR-2 IIIb mRNA levels were not altered, 
whereas FGFR-2 IIIc mRNA levels were significantly increased (P<0.01) by comparison 
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with siNeg cells (Supplemental Fig. 6A). Moreover, ESRP1 protein levels were markedly 
decreased in both the cytoplasmic (cyt) and nuclear (nu) fractions of siESRP1-A and 
siESRP1-B cells (Supplemental Fig. 6B), without any evident morphological changes 
(Supplemental Fig. 6C, upper panels) but with a marked decrease in nuclear ESRP1 
immunofluorescence (Supplemental Fig. 6C, lower panels). As compared with siNeg cells, 
siESRP1-A and siESRP1-B cells also exhibited increased proliferation (P<0.05, Fig. 5A), as 
well as increased (P<0.01) migration (Fig. 5B) and invasion (Fig. 5C).
We previously reported that FGFR-2 IIIc is associated with enhanced proliferation, 
migration, and invasion in pancreatic cancer cells (10). To determine whether such increases 
were due to increased FGFR-2 IIIc expression, we performed double knockdown of ESRP1 
and FGFR-2 IIIc in KLM-1 using ESPR1 siRNA and FGFR-2 IIIc siRNA (siESRP1-A + 
siFGFR-2 IIIc and siESRP1-B + siFGFR-2 IIIc). An irrelevant siRNA was used as a 
negative control (siESRP1-A + siNeg and siESRP1-B + siNeg). FGFR-2 IIIc mRNA levels 
were significantly higher (P<0.01) in siESRP1-A + siNeg and siESRP1-B + siNeg by 
comparison with parental or siNeg cells, and were significantly decreased (P<0.01) by 
siESRP1-A + siFGFR-2 IIIc or siESRP1-B + siFGFR-2 IIIc (Supplemental Fig. 7A). 
Moreover, ESRP1 silencing with siESRP1-A or -B was associated with increased 
proliferation, migration and invasion, whereas in the presence of siFGFR-2 IIIc the cells 
were no longer growth-stimulated, and migration and invasion were inhibited (Supplemental 
Fig. 7B–D). Thus, suppression of ESRP1 enhances FGFR-2 IIIc expression and promotes 
pancreatic cancer cell proliferation, migration and invasion, and these deleterious effects can 
be blocked by suppressing FGFR-2 IIIc expression.
Proteomic Analysis of ESRP1-transfected PANC-1 Cells
ESRP1 has been reported to play important roles in ESRP-regulated splicing network of 
hundreds of alternative splicing events within numerous genes with functions in cell-cell 
adhesion, polarity, and migration (19). To examine the proteins which are regulated by 
ESRP1, we performed 2-dimentional electrophoresis using transient ESRP1-expression 
vector transfected PANC-1cells, and identified eight spots whose expression levels were 
altered at a two-fold cut-off as compared with PANC-EV cells, and then identified these 
proteins using software. Transient ESRP1-transfected PANC-1 cells exhibited decreased 
expression of vimentin, 14-3-3ε, heat shock protein 70 (HSP 70), and the IQ motif 
containing GTPase activating protein 1 (IQGAP1), and increased expression of valosin 
containing protein (VCP), α-enolase (ENO1), filamin-α (FLNA), and perilipin 3 (PLIN3) 
(Table 1) . To validate these results, we performed quantitative PCR using RNA from 
PANC-1 cells transiently overexpressing ESRP1, and from KLM-1 transfected with 
siESRP1. Vimentin, 14-3-3ε, HSP 70, and IQGAP1 mRNA levels were decreased in ESRP1 
overexpressing PANC-1cells (Supplemental Fig. 8). Conversely, VCP, ENO1, and FLNA 
mRNAs were decreased in siESRP1 expressing KLM-1 cells (Supplemental Fig. 9). These 
results were consistent with the data obtained by 2-dimentional electrophoresis. Except for 
FLNA, there are no previous reports about splicing variants for these mRNA moieties. PCR 
analysis for the common site for FLNA and its splicing variant yielded similar results, 
leading us to conclude that ESRP1 did not regulate the splicing of FLNA.
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We analyzed protein levels by immunoblotting in addition to analyzing the levels of 
differentially expressed proteins by proteomic analysis. Western blot analysis using anti-
IQGAP1, FLNA and PLIN3 antibodies confirmed that ESRP1 modulated the levels of these 
proteins (Supplemental Fig. 10) in parallel with the observed changes observed by mass 
spectrometry (Table 1) and at the mRNA level (Supplemental Fig. 8). With respect to 
14-3-3ε, the protein levels were only minimally decreased by ESRP1, but silencing ESRP1 
in KLM-1 cells resulted in its upregulation (Supplemental Fig. 10). By contrast the changes 
in vimentin, HSP70, VCP, and ENO1 were subtle and inconsistent. Thus, both proteins that 
were either most decreased or most increased by ESRP1 based on the proteomics analysis 
are most likely true RNA binding targets for ESRP1.
ESRP1 suppressed EMT induced by TGF-β in PANC-1 cell
EMT is associated with enhanced cancer cell invasiveness (20), and several of the proteins 
identified by 2-dimentional electrophoresis, such as vimentin, have been implicated as 
modulators of EMT. In view of the important role of TGF-β1 in promoting EMT in PDAC 
cells, we next sought to determine whether ESRP1 levels modulated the actions of TGF-β1 
on EMT. TGF-β1 (20 ng/ml) induced morphological changes associated with EMT in 
PANC-1 cells, and down-regulated E-cadherin while up-regulating vimentin in these cells at 
24 and 48 hours following its addition to the medium (Supplemental Fig. 11A and B). When 
PANC-EV and PANC-ESRP1 cells were incubated with TGF-β1 (20 ng/ml) for 48 hours, 
PANC-EV cells changed from cobblestone-like to spindle-shaped, whereas the morphology 
of PANC-ESRP1 cells was not altered (Supplemental Fig. 11C). Moreover, basal E-cadherin 
mRNA levels were higher in PANC-ESRP1 cells (P<0.05) than that in PANC-EV cells, and 
basal vimentin levels were lower in PANC-ESRP1 cells (P<0.01) than in PANC-EV cells 
(Supplemental Fig. 11D and E).
Effects of ESRP1 expression in PANC-1 and KLM-1 cells on additional receptors
To assess the generality of the effects of ESRP1, we next examined the consequences of its 
increased expression on the alternative splicing of FGFR-1, FGFR-3, and CD44 
(Supplemental Fig. 12A–C). ESRP1 overexpression resulted in an increase in the ratio of 
FGFR-1 IIIb/IIIc by comparison with control cells, without altering FGFR-3 IIIb/IIIc or 
CD44s/CD44 ratios, whereas in ESRP1 suppressed KLM-1 cells, the ratios of FGFR-1 IIIb/
IIIc and FGFR-3 IIIb/IIIc were significantly lower than in KLM-1 control cells, and the 
CD44s/ total CD44 ratio was significantly increased.
Effects of ESRP1 on orthotopic tumor formation and liver metastasis in NOG mice
PANC-EV2 and PANC-EV9 cells and ESRP1-2 and ESRP1-5 cells readily formed tumors 
following subcutaneous implantation in nude mice. However, there were no significant 
differences in tumor growth between PANC-EV2 and PANC-EV9 cells and ESRP1-2 and 
ESRP1-5 cells over time (Supplemental Fig. 13).
Small fragments from these tumors were then implanted orthotopically in the pancreas of 
NOG mice, yielding pancreatic tumors that tended to be smaller in volume and lighter in 
weight when derived from ESRP1-2 and ESRP1-5 cells by comparison with the PANC-EV-
derived tumors, but these differences were not statistically significant (Fig. 6A). By contrast, 
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the ESRP1-2 and ESRP1-5 tumors exhibited a markedly decreased incidence of hepatic and 
pulmonary metastases by comparison with PANC-EV2 and 9 (Fig. 6B–C). The metastases 
were of human origin as demonstrated by positive human leukocyte antigen (HLA) class I 
immunoreactivity, which is expressed in cells of human but not mouse origin (Fig. 6B–C). 
Moreover, the percent of HLA class I positive cancer area/total tissue area was dramatically 
reduced in ESRP1-2 and ESRP1-5 tumors when compared with PANC-EV2 and 9 tumors, 
in the case of both hepatic (P<0.01, Fig. 6B) and pulmonary metastases (P<0.01, Fig. 6C). 
Interestingly, most of the mice implanted orthotopically with PANC-EV cells exhibited 
marked weight loss and cachexia and one mouse died. All the mice were sacrificed at that 
point due to animal ethics considerations. At that time point, all of the ESRP1 implanted 
mice appeared healthy and in stable condition, and did not exhibit cachexia.
Discussion
PDAC often arises from precursor lesions called pancreatic intraepithelial neoplasia (PanIN) 
that progress from low to high grade, to invasive and metastatic cancer (21–23). Major 
driver mutations in PDAC include mutated Kras (99% incidence), p53 (70%), Smad4 (55%) 
and p16 (85%), overexpression of multiple tyrosine kinase receptors and ligands, and 
overexpression of TGF-βs (24, 25). PDAC patients often exhibit distant metastases, 
especially to the liver and lung (26). PDAC is also associated with overexpression of FGF 
ligands and an intense desmoplasia (27, 28). Although the molecular mechanisms that 
modulate pancreatic cancer cell metastasis are not known, it is well established that the 
underlying processes are complex and multifactorial, and that the microenvironment, the 
immune system, and that both genetic and epigenetic alterations in cancer cells contribute to 
the metastatic process (29–31).
EMT represents an additional crucial mechanism for enhancing the ability of cancer cells to 
spread and metastasize (20). Many of the alterations that are associated with EMT may be 
affected through a repertoire of alternative splicing events which are regulated by key 
splicing factors such as ESRP1. In the present study we determined that ESRP1 was 
abundant in well-to-moderately differentiated cancers which also expressed high FGFR-2 
IIIb levels, but its expression was decreased in poorly-differentiated cancers which 
expressed relatively high levels of FGFR-2 IIIc. These observations raise the possibility that 
increased ESRP1 levels lead to elevated levels of FGFR-2 IIIb and an epithelial rather than a 
mesenchymal phenotype that could reflect less aggressive disease. Five observations support 
this conclusion. First, elevated expression of ESRP1 was associated with prolonged survival. 
Second, PANC-1 cells engineered to express ESRP1 exhibited increased FGFR-2 IIIb 
expression and decreased migration and invasion in vitro. Third, ESRP1 blunted TGF-β-
mediated induction of EMT. Fourth, silencing ESRP1 in KLM-1 cells was associated with 
increased FGFR-2 IIIc expression and increased cell growth, migration and invasion, and 
these changes were blocked by silencing FGFR-2 IIIc. Fifth, ESRP1 overexpressing 
PANC-1 clones formed significantly fewer hepatic and pulmonary metastases as compared 
with control clones.
ESRP1 and ESRP2 are act as central coordinators of an alternative splicing network that 
underlies EMT (14, 19). In our study, increased ESRP1 expression changed cell morphology 
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from spindle shaped to cobblestone, prevented TGF-β1-induced morphological alterations 
that are associated with EMT, and suppressed cancer cell invasion. These alterations have 
been correlated with a mesenchymal to epithelial transition (MET) process (32). Moreover, 
high ESRP1 expression was associated with well to moderately differentiated lesions, low 
histological grades and improved survival. Together with the observation that ESRP1 
repressed cell migration and invasion, our findings suggest that low ESRP1 levels contribute 
to enhanced EMT in PDAC.
Alternative splicing is now recognized to expand transcriptomic diversity and nearly all 
multi-exon human genes undergo alternative splicing (33, 34). Previous reports have shown 
that ESRP1 directly binds to the ISE/ISS-3 element of the FGFR-2 gene and induces 
expression of FGFR-2 IIIb (13). In the present study, transient transfection of ESRP1 in 
PANC-1 cells increased FGFR-2 IIIb mRNA levels, without altering FGFR-2 IIIc 
expression, perhaps due to the existence of additional mechanisms that regulate FGFR-2 IIIc 
expression. However, stable transfection of ESRP1 in PANC-1 cells yielded clones that 
either did not change expression of FGFR-2 IIIb or IIIc, or increased the expression of both 
receptors, underscoring the complexity of this splicing regulation. Nonetheless, in both 
clones, there was an increase in the ratio of FGFR-2 IIIb to FGFR-2 IIIc, and both clones 
exhibited decreased motility. The importance of ESPR1 in the modulation of FGFR2 
isoform expression is highlighted by our observation that suppression of ESRP1 in KLM-1 
cells consistently increased FGFR-2 IIIc mRNA levels without altering FGFR-2 IIIb 
expression, revealing that a 50% decrease in endogenous ESRP1 levels increased FGFR-2 
IIIc for 2 to 3-fold. The biological significance of this increase is highlighted by the 
simultaneous knockdown of FGFR2IIIc and ESRP1 in KLM-1 cells which demonstrated 
that the increases in proliferation, migration and invasion induced by ESRP1 were 
eliminated by concomitantly down-regulating FGFR2IIIc expression.
Our results do not exclude the possibility that some of the observed biological effects in the 
present study could be due to ESRP1’s ability to modulate the splicing of numerous 
additional mRNA moieties. To explore this possibility, we performed proteomic analysis 
using transiently ESRP1-transfected PANC-1 cells. Most of the proteins thus identified are 
involved in the modulation of cell proliferation, migration, and invasion. Moreover, 
vimentin, has a well-known role in EMT. In addition, IQGAP1 is a large (189 kDa) scaffold 
protein that binds F-actin, helps promote cell migration, proliferation, and tumorigenesis 
(35). IQGAP1 also facilitates caveolae insertion into the plasma membrane (36), thereby 
helping to promote EMT (37). Similarly, 14-3-3ε promotes invasion of gastric cancer cells, 
and may promote EMT in these cells (38). Thus, the ability of ESRP1 to suppress both 
IQGAP1 and 14-3-3ε is consistent with its ability to suppress EMT. Recently, a splicing 
sensitive microarray platform was used to characterize ESRP-regulated splicing regulatory 
networks and identified hundreds of novel ESRP-regulated splicing events, but did not 
detect the candidate proteins identified and validated in our study (19). Moreover, there are 
no previous reports of alternative splicing variants of these potential target proteins, except 
for filamin alpha, underscoring the novelty of our findings and raising the possibility that 
these types of splicing events are context and cell dependent.
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ESRP1 also modulated splicing of additional mRNA moieties in pancreatic cancer cells, as 
evidenced by our finding that its suppression resulted in alternative splicing of FGFR-1, 
FGFR-3, and CD44. CD44s has been implicated in promoting EMT (39) and its up-
regulation in KLM-1 cells following ESRP1 silencing further confirms that ESRP1 acts by 
modulating multiple splicing events to suppress pancreatic cancer cell metastasis. In 
agreement with these observations, ESRP1 binds to 5'UTR of mRNAs and causes alterations 
in protein levels of several cancer related genes including c-myc, cyclin D1, p21, PKCα, 
integrin β and E-cadherin (15). Taken together with our present findings, these observations 
suggest that ESRP1 exerts an important role in metastasis-suppression in PDAC by 
modulating the expression of splice variants of many important mRNA moieties implicated 
in EMT. Given that EMT may lead to cancer cell dissemination from the pancreas even 
prior to tumor formation (40, 41), devising mechanisms to up-regulate ESRP1 may represent 
a novel chemopreventive and therapeutic approach for suppressing EMT and metastasis in 
PDAC.
Materials & Methods
Materials
The following were purchased: anti-ESRP1, anti-lamin A+C, anti-Perilipin 3, and anit-
IQGAP1 antibodies from Abcam plc (Cambridge, MA); anti-filamin A from Novus 
Biologicals (Colorado, USA); anti-14-3-3ε from Cell signaling technology (Boston, MA); 
anti-CD31 antibody from AbD Serotec (Kidlington, UK); anti-cytokeratin (CK) 19 antibody 
from Boehringer Mannheim GmbH (Mannheim, Germany); anti-insulin antibody from 
DAKO JAPAN (Tokyo, Japan); anti-HLA class I-A, B, C antibody from Hokudo Co., Ltd. 
(Tokyo, Japan); Histofine Simple Stain MAX PO (M) and (R) kits from Nichirei (Tokyo, 
Japan); FastPure RNA kit and pBApo-CMV Neo DNA vector from Takara Bio Inc. (Tokyo, 
Japan); TaqMan Gene Expression Assays for ESRP1 (Hs00214472_m1), CD44s 
(Hs01081473_m1), CD44v (Hs00153304_m1), E-cadherin (Hs01012953_m1), Vimentin 
(Hs00185584_m1), HSP 70 (Hs03044880_gH), VCP (Hs00997642_m1), ENO1 
(Hs00361415_m1), IQGAP1 (Hs00896595_m1), 14-3-3ε (Hs00356749_g1) FLNA 
(Hs00924645_m1, Hs00926963_m1), PLIN3 (Hs00998416_m1), and 18S rRNA 
(Hs99999901_s1), and siRNAs targeting human ESRP1 (s29571, 29572) and negative 
control siRNA (Silencer select Negative control #2) from Life Technologies Corporation 
(Carlsbad, CA), We prepared 2 different types of TaqMan primers for filamin alpha: one is 
specific for a splicing variant and the other is for common site of native filamin alpha and its 
splicing isoforms.; FuGene HD transfection reagent from Roche Diagnostics (Mannheim, 
Germany); TransIT-siQUEST Transfection Reagent from Mirus Bio LLC (Madison, WI); 
NE-PER nuclear and cytoplasmic extraction reagent from Thermo Fisher Scientific 
(Waltham, MA); WST-8 cell counting kit from Wako Pure Chemical Industries (Osaka, 
Japan); BioCoat Matrigel invasion chamber (8 µm pore size) from BD Bioscience (Franklin 
Lakes, NJ); immobilized pH gradient (IPG, pH4-7) strips and Oriole Fluorescent Gel Stain 
Kit from Bio-Rad laboratories (Hercules, CA); recombinant human ESRP1 (H00054845-
P01) and recombinant human ESRP2 (H00080004-P01) from Novus Biologicals (Colorado, 
USA); recombinant human TGF-β1 from R&D Systems (Minneapolis, MN); and L-column 
Micro from Chemicals Evaluation and Research Institute (Tokyo, Japan). All other reagents 
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were purchased from Sigma-Aldrich Corporation (St. Louis, MO). Anti-human ESRP1&2 
antibody was a kind gift from Dr. Russ P Carstens (University of Pennsylvania School of 
Medicine, Philadelphia, PA) (19).
Human PDAC tissues
One hundred twenty three PDAC patients who participated in this study were receiving 
treatment at Nippon Medical School Hospital (Tokyo, Japan) from 1995 to 2011. The 
clinicopathological stage was determined according to the TNM classification system of the 
International Union Against Cancer (UICC). Normal pancreata were obtained from patients 
who underwent partial pancreatectomy due to the presence of a benign heterotopic spleen in 
the pancreas (n=8). This study was carried out in accordance with the principles embodied in 
the Declaration of Helsinki, 2008, and informed consent for the usage of pancreatic tissues 
was obtained from each patient.
Immunohistochemistry
Paraffin-embedded serial tissue sections (3.5 µm thick) were subjected to immunostaining 
using the Histofine Simple Stain Max-PO kits. Rabbit polyclonal anti-FGFR-2 IIIb (2) and 
IIIc antibodies (10, 42) were prepared as previously reported. Sections were then incubated 
overnight with the appropriate antibody (1:50 for ESRP1, 1:500 for FGFR-2 IIIb, 1:250 for 
FGFR-2 IIIc, 1:50 for CD31, 1:100 for CK19, 1:1,000 for insulin). For the evaluation of the 
intensity and positive proportion of ESRP1, FGFR-2 IIIb and FGFR-2 IIIc immunostaining, 
the following scale was employed: 0, no staining; 1+, mild staining; 2+, moderate staining; 
and 3+, intense staining,: 0, no staining; 1+,1–30%; 2+, 31–60%; 3+, >60%, positive 
proportion in cancer cells (43).
Pancreatic Cancer Cell Lines
PANC-1, MIA PaCa-2, KLM-1, PK-1, PK-8, and PK-45H, human PDAC cell lines were 
obtained from the Cell Resource Center for Biomedical Research, Institute of Development, 
Aging and Cancer, Tohoku University (Sendai, Japan), and Capan-1 cells were purchased 
from American Type Culture Collection (Manassas, VA). Cell lines were authenticated by 
short tandem repeat profiling analysis (March 2012).
Quantitative RT-PCR (qRT-PCR
qRT-PCR was performed with the StepOnePlus PCR system (Life Technologies 
Corporation) using specific primers and a TaqMan probe (10). qRT-PCR results were 
expressed as the ratio of target to 18S rRNA, the latter serving as an internal standard. Gene 
expression levels were measured in triplicate.
Construction of ESRP1 and FGFR-2 IIIc -expression-vector, and generation of transiently 
and stably transfected cells
The full-length ESRP1 cDNA fragment was ligated into pBApo-CMV Neo DNA vector. 
The full-length FGFR2IIIc cDNA fragment was ligated to the 3′ end of the human 
cytomegalovirus early promoter/enhancer in the eukaryotic expression vector pIRES2-
EGFP. PANC-1 cells (1 × 105) were transfected with 5 µg of DNA using FuGENE HD, and 
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used in experiments 72 hours later. To prepare stable transfected clones, cells were passaged 
and cultured with Geneticin (1,000 µg/ml).
Transfection of siRNA targeting ESRP1 and FGFR-2 IIIc
We used 2 types of siRNA targeting different sites in ESRP1 mRNA; siESRP1-A and 
siESRP1-B. Sense ESRP1 siRNA sequences of siESRP1-A and siESRP1-B were 5’-
CCUUCGAGGUCUUCCCUAU-3’, and 5’-GCAGCAAGAUGGAACUUAU-3’, 
respectively. Each siRNA stock solution and TransIT-siQUEST were mixed in serum-free 
medium. In preliminary experiments, the optimal concentration of siRNAs targeting ESRP1 
was determined to be 2.5 nM by qRT-PCR for ESRP1. The custom designed siRNA against 
specific IIIc region of FGFR2 IIIc were purchased, and the sense sequence was 5’-GUG-
CUU-GGC-GGG-UAA-UCC-Utt-3’ (s275291). The cells were plated at a density of 1×105 
cells in a 35 mm dish and transfected with 5 nM siRNAs for FGFR2 IIIc(10).
Western blot analysis
Cytoplasmic (cyt) and nuclear protein (nu) were separately extracted using the NE-PER 
extraction reagents. Lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) using non-reducing conditions for the anti-ESRP1&2 
antibodies, and reducing conditions for the other antibodies. The separated proteins were 
transferred to membranes, which were then incubated overnight with the anti-ESRP1&2 
antibodies (1:1000 in dilution). Membranes were reblotted with a mouse anti-β-actin 
antibody (1:5000 in dilution) and anti-lamin A+C antibody (1:1000 in dilution). The anti-
ESRP1 antibody (Sigma) which was used in immunohistochemical and fluorescence 
staining was not suitable for western blotting. Therefore, we used an ESRP antibody for 
western blotting which detected both ESRP1 and ESRP2 (13).
Immunofluorescence Staining
Cells were fixed with 4% paraformaldehyde, incubated with 0.1% of Triton-X for five 
minutes, and overnight at 4°C with the anti-ESRP1 antibody (1:100). Fluorescent images 
were observed under a Digital Eclipse C1 TE2000-E microscope (Nikon Instech Co., Ltd., 
Tokyo, Japan) (44). The confocal settings including laser power and detector sensitivity 
were unchanged during the acquisition of all images.
Cell proliferation assays
Cells were cultured in RPMI 1640 medium with 10% FBS at a density of 5×103 in 96-well 
plates followed by incubation for 24, 48 or 72 hours. Cells were then incubated with WST-8 
cell counting reagent for 4 hours. Optical density was measured using a plate reader (Bio-
Rad Laboratory, Hercules, CA) at 450 nm.
Single cell movement assay
To assess cell migration, single cell movement assay was performed (10). Cells (5,000 per 
well) were seeded onto four-well glass bottom dish. Cell movement was monitored for 24 
hours by a Digital Eclipse TE 2000-E motorized inverted microscope (Nikon Insteck Co., 
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Ltd.). The total distance of individual cells covered within 24 hours was determined using 
the Metamorph software 7.6 (Universal Imaging Corp. Ltd., Buckinghamshire, UK).
Boyden chamber assays
Migration and invasion assays were carried out using a modified Boyden chamber 
technique. The cells on the upper surface of the filter were carefully removed with a cotton 
swab, after 8 hours for PANC-1 cells and after 20 hours for KLM-1 cells, due to the slower 
migration of KLM-1 cells. These time points were selected based on preliminary data (44). 
Cell numbers on each membrane were counted in five high-power fields (x 200). Cell 
invasion assays were performed using the matrigel coating inserts, and cell counting was 
performed as above.
Two-dimensional electrophoresis (2DE) and imaging
Two-dimensional gel electrophoresis was carried out by the method of Gorg et al. (45, 46) 
with modifications. First-dimension isoelectric focusing gel electrophoresis was carried out 
by using an electrophoresis apparatus from Nihon Eido (Tokyo, Japan) at 200 V for 30 min, 
at 400 V for 30 min, at 1,000 V for 1 h, and at 2,000 V for 15 to 16 h. Then, the second-
dimensional SDS-PAGE was performed using a 10% acrylamide gel. After electrophoresis, 
the gels were stained with Oriole Fluorescent Gel Stain Kit. The gels were visualized using 
ChemiDoc XRS system (Bio-Rad, Hercules, CA) and analyzed using PDQuest 2D-image-
analysis software (Bio-Rad).
Protein identification using mass spectrometry
The protein spots were excised manually and then digested using In-gel Tryptic Digestion 
Kit according to the manufacturer’s protocol. Liquid chromatography was performed using 
an Advance-nano UHPLC (AMR Inc., Tokyo, Japan). The eluents used were: A, 0.1% 
formic acid in water, and B, acetonitrile. Peptides generated by tryptic digestion were loaded 
onto a L-column Micro (C18, 3 µm, 0.1 × 50 mm) and separated at flow rate of 500 nl/min 
with the concentration gradient of acetonitrile from 5% B to 45% B in 30 min. Gradient-
eluted peptides were analyzed using an amaZon ETD ion-trap mass spectrometer (Bruker 
Daltonics, Billerica, MA). The data were acquired in a data-dependent manner, in which 
MS/MS fragmentation was performed on the 10 most intense peaks of every full MS scan. 
All MS/MS spectra data were searched against the SwissProt using Mascot (Matrix Science, 
London, UK).
Effects of TGF-β1 in ESRP1-overexpressing PANC-1 cells
The ESRP1-expression-vector was transfected into PANC-1 cells which were then 
incubated for 24 hours. Recombinant human TGF-β1 (20 ng/ml) was then added to the 
incubation medium, and cells were incubated for 24 and 48 hours. RNA samples were then 
extracted.
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Heterotopic and orthotopic implantations of ESRP1-overexpressed PANC-1 cells in 
immunodeficient mice
Six-week-old male nude mice (BALB/cA Jcl-nu/nu; CLEA Japan Inc, Tokyo, Japan) were 
subcutaneously injected in the both flanks with 1×106 PANC-EV2, PANC-EV9, ESRP1-2 
and ESRP1-5 cells/mouse (n=3). Four weeks later, the subcutaneous tumors were excised. 
To evaluate tumor growth in an orthotopic model, we used NOD/Shi-scid, IL-2ãnull (NOG; 
Central Institute for Experimental Animals, Kanagawa, Japan) mice (47). Tumor fragments 
from subcutaneous tumors (2 mm square) were sutured onto the surface of the tail of the 
pancreas of 6 week-old, male, NOG mice (n=3 per cell line) (10, 48). Animals were 
monitored for five weeks, and pancreatic tumors, lungs and livers were excised, weighed 
and processed for HLA class I immunostaining to mark cells that were of human origin. 
Quantitative morphometry was performed to determine the percent of HLA class I positive 
cancer area/total tissue area on five distinct areas, using WinROOF (Mitani Corporation, 
Fukui, Japan) (44). The experimental protocol was approved by the Animal Ethics 
Committee of Nippon Medical School.
Statistical analysis
All quantitative data were presented as mean±SEM values. Data for two groups were 
compared using Student’s t test. The data between multiple groups were compared using 
one-way ANOVA. The chi-square test and Fisher’s exact test were used to analyze the 
correlation between ESRP1-expression and clinicopathological features. Cumulative 
survival rate was calculated with the Kaplan-Meier method, and the significance of 
differences in survival rates was analyzed by the log-rank test. P<0.05 was considered as 
statistically significant. Computations were performed using the Stat View J version 5.0 
software package (SAS Institute, Inc.).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Immunohistochemical Analysis of ESRP1, FGFR-2 IIIb and FGFR-2 IIIc in Human 
Pancreatic Cancer Tissues
A: ESRP1 was strongly expressed in the nuclei of cancer cells in PDAC sections, especially 
in well-to-moderately differentiated adenocarcinoma forming ductal structure (arrows), 
while it was weakly expressed in poorly-differentiated adenocarcinoma, which are 
characterized by trabecular or solid structure, but not ductal structure. In serial tissue 
sections, high ESRP1 expression was associated with stronger immunostaining for FGFR-2 
IIIb (white arrows), whereas FGFR-2 IIIc immunoreactivity was increased in tumors with 
low ESRP1 levels (arrowheads). Upper panel, H&E staining; bar; 100 µm. B and C: ESRP1 
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and FGFR-2 IIIb indices in well/moderate differentiated (well/mod) lesions were 
significantly higher than in poorly-differentiated (poor) lesions (**P<0.01). D: The FGFR-2 
IIIc index was greater in poor lesions (*P<0.05).
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Figure 2. Overall Survival and Disease-free Survival of High-ESRP1 and Low-ESRP1 groups
A: The overall survival rate of the group exhibiting high ESRP1 immunoreactivity was 
significantly higher than that of the low-immunoreactivity ESRP1 group (P=0.0189). B: The 
disease-free survival rate of the high ESRP1 group tended to higher than that of the low 
ESRP1 group (P=0.0767).
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Figure 3. Effects of Transfecting an ESRP1-expressing Vector in PANC-1 Cells
A: Quantitative PCR. PANC-1 cells that were transiently transfected with an ESRP1-
expressing vector (PANC-ESRP1) exhibited higher ESRP1 mRNA levels than empty 
vector-transfected cells (PANC-EV) and wild-type (PANC-1) cells (**P<0.01). PANC-
ESRP1 expressed higher levels of FGFR-2 IIIb mRNA than PANC-EV and PANC-1 cells, 
while FGFR-2 IIIc expression was not altered. B: Western blots. ESRP1 protein was 
increased in the nuclear fraction of PANC-ESRP1 cell (PANC-ESRP1 nu) as compared to 
the nuclei of PANC-1 and PANC-EV cells (PANC-1 nu and PANC-EV nu). Lamin A + C, 
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which is a marker of nuclear protein, was not detected in cytoplasm (cyt), and was abundant 
in the nuclear fraction (nu). β-actin immnoblotting was used to assess protein loading. rb 
ESRP1 and rb ESRP2 represent recombinant ESRP1 and ESRP2, respectively. C: In phase-
contrast images, there were no characteristic morphological changes in PANC-1, PANC-EV 
and PANC-ESRP1 cells (upper panel). Immunofluorescence images of ESRP1 (green) 
showed significant increases of ESRP1 protein in PANC-ESRP1 cells as compared with 
PANC-1 and PANC-EV cells (lower panel). Upper panel: bar: 100µm, inset of lower panel: 
bar: 50 µm.
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Figure 4. Effects of ESRP1 on Proliferation, Migration and Invasion in PANC-1 Cells
A: Cell proliferation. Cell proliferation was similar in PANC-1, PANC-EV and PANC-
ESRP1 cells at all tested time points. B: Single cell movement. PANC-ESRP1 cells 
movement was significantly decreased as compared with PANC-1 and PANC-EV cells 
(**P<0.01). bar: 500 µm. C and D: Both migration (C) and invasion (D) were markedly 
decreased in PANC-ESRP1 cells as compared with PANC-EV cells (**P<0.01). bar: 
200µm.
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Figure 5. Effects of ESRP1 Silencing on Cell Proliferation, Migration and Invasion in KLM-1 
Cells
A: Cell proliferation. ESRP1 siRNA-transfected KLM-1 cells were transfected with siRNA 
targeting ESRP1 (siESRP1-A and siESRP1-B) and cell proliferation was monitored using 
the WST-8 cell counting assay. There was a significant increase in cell proliferation in both 
siESRP1-A and siESRP1-B cells as compared with negative control siRNA-transfected cells 
(siNeg, *P<0.05). B and C: Migration and invasion. Both migration and invasion were 
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markedly increased in siESRP1-A and siESRP1-B cells as compared with siNeg cells 
(**P<0.01). bar: 200µm.
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Figure 6. Effects of ESRP1 on Orthotopic Tumor Growth and Metastasis in NOG Mice
A: Tumor growth. Pancreatic tumors derived from PANC-EV cells were larger (left panel) 
and heavier (right panel) than tumors derived from ESRP1-transfected cells, but these 
differences were not statistically significant (n=3 in each group). Bar: 10 mm. B: Hepatic 
metastases. ESRP1-2 and ESRP1-5 cells exhibited fewer hepatic metastases by comparison 
with PANC-EV2 and 9 cells. Consequently, the percentage of human HLA class I positive 
cancer areas/total liver areas was markedly decreased in ESRP1-2 and ESRP1-5 tumors 
(**P<0.01). C: Pulmonary metastases. ESRP1-2 and ESRP1-5 cells also exhibited a 
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markedly decreased incidence of pulmonary metastases, as evidenced by the lower 
percentage of human HLA class I positive cancer areas/total liver areas in ESRP1-2 and 
ESRP1-5 derived tumors (**P<0.01). bars: 10 mm and 0.1 mm in B; 5 mm and 0.2 mm in 
C.
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